Overall survival in patients with advanced stage Hodgkin’s Lymphoma improves on Brentuximab Vedotin
Brentuximab Vedotin plus chemotherapy as first-line treatment improves the overall survival in patients suffering from stage III or IV Hodgkin’s Lymphoma. Get an update on the ECHELON-1 trial by investigator Stephen Ansell in this MEDtalk.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
